medigraphic.com
ISSN 0210-5187 (Electronic)

2017, Number 3

<< Back Next >>

Med Cutan Iber Lat Am 2017; 45 (3)

Neurolysis in Maranhao: are time and nerves lost?

Matos VTA, Aguiar AM, Zaban CJ, Alberto ADF, Tadeu VR, Fortes BVAC

Language: Portugués
References: 24
Page: 204-209
PDF size: 276.80 Kb.


ABSTRACT

Introduction: Leprosy is an infectious disease that can be responsible for the development of numerous consequences resulting from nerve damage. Although the intrinsic nerve compression responds well to corticosteroids, extrinsic compression, which occurs in osteofibrous tunnels, does not respond well to drug therapy, and a frequent therapeutic option is surgical decompression-neurolysis. Objectives: To outline the clinical and epidemiological profile of patients undergoing neurolysis between January 2013 and June 2016. Material and methods: This is a cross-sectional, observational and quantitative study in which the medical records of 141 patients who underwent neurolysis were reviewed. The Registration Form for Physical Disabilities was an important tool regarding the evaluation of existing disability in the first outpatient neurolysis clinic. In this regard, the option was to analyze exclusively the data corresponding to the dermatome that was later approached by surgery. Results: One hundred forty-one patients were addressed in the study, of which 87 were classified as borderline; ulnar (72) and tibial (61) nerves were the ones that required decompression more frequently. The average age at diagnosis was 32.77 years, and the time of evolution until neurolysis, 3.13 years. All patients received prednisone; however, only 28 received thalidomide. Finally, 23 underwent more than one neurolysis (in different nerves at each time). Conclusion: The dismantling of the Leprosy Service at the University Hospital of UFMA clearly deprives patients of a more immediate assistance in situations of neural suffering, given that 37.75% of the cases followed had already an important sensory and motor loss in their first consultations.


REFERENCES

  1. Ministério da Saúde. As diretrizes para vigilância, atenção e controle da hanseníase. Brasília: Ministério da Saúde; 2010.

  2. De Alencar CH, Ramos Jr. AN, De Sena NS, Murto C, Freitas AM, Caracas BJ, Heukelbach J. Leprosy diagnosis in municipalities other than the patients’ place of residence: spatial analysis, 2001-2009. Cad Saúde Pública. 2012; 28 (9): 1685-1698.

  3. Rodrigues LC, Lockwood DN. Leprosy now: epidemiology, progress, challenges, and research gaps. Lancet Infect Dis. 2011; 11 (6): 464-470.

  4. Martyn CN, Hughes RA. Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry. 1997; 62: 310-318.

  5. Orsini M, De Freitas MR, De Souza AR, Pimentel MM, Reis JP, Mero RC et al. Estudos clínicos, imunopatológicos e eletro siológicos dos nervos periféricos na hanseníase. Rev Neurocienc. 2008; 16 (3): 220-230.

  6. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância Epidemiológica. Vigilância em saúde: situação epidemiológica da hanseníase no Brasil. Brasília: Ministério da Saúde; 2008.

  7. Sundar R, PSS et al. Multi-centre, double blind, randomized trial of three steroid regimens in the treatment of type-1 reactions in leprosy. Lepr Rev. 2006; 77, 25-33.

  8. Araújo AE, Araújo DM, Goulart IM, Pereira SR, Figueiredo IA, Serra HO et al. Complicações neurais e incapacidades em hanseníase em capital do nordeste brasileiro com alta endemicidade. Rev Bras Epidemiol. 2014; 17 (4): 899-910.

  9. Barbosa JC, Ramos JA, Alencar OM, Pinto MS, Castro CG. Atenção pós-alta em hanseníase no Sistema Único de Saúde: aspectos relativos ao acesso na região nordeste. Cad Saúde Coletiva. 2014; 22 (4): 351-358.

  10. Melão S, De Oliveira BL, Mounzer N, Denipotti CV, De Azevedo SW. Perfil epidemiológico dos pacientes com hanseníase no extremo sul de Santa Catarina, no período de 2001 a 2007. Rev Soc Bras Med Trop. 2011; 44 (1): 79-84.

  11. Monteiro LD, Alencar CH, Barbosa JC, Braga KP, Castro MD, Heukelbach J. Incapacidades físicas em pessoas acometidas pela hanseníase no período pós-alta da poliquimioterapia em um município no Norte do Brasil. Cad Saúde Pública. 2013; 29 (5): 909-920.

  12. Flach DM, Andrade M, Valle CLP, Pimentel MIF, Mello KT. Análise da série histórica do período de 2001 a 2009, dos casos de hanseníase em menores de 15 anos no estado de RJ. Hansen Int. 2010; 35 (1): 13-20.

  13. Marques GF, Barreto JA, Sousa JMP, Brandão LSG. Alternative treatment of multibacillary leprosy in a case of hepatotoxicity during multidrug therapy. Hansenol Int. 2012; 37 (2): 81-85.

  14. Crespo MJ, Gonçalves A. Avaliação das possibilidades de controle da hanseníase a partir da poliquimioterapia. Rev Port Saúde Pública. 2014; 32 (1): 80-88.

  15. Sgobbi FC, Prado TC, Andrade GD, Mendes AD, Donato TN, Rosini SJ et al. Grau de incapacidade física de portadores de hanseníase: estudo de coorte retrospectivo. Arquivos de Ciências da Saúde. 2015; 22 (4): 58-62.

  16. Barbosa DR, Almeida MG, Dos Santos AG. Características epidemiológicas e espaciais da hanseníase no Estado do Maranhão, Brasil, 2001-2012. Medicina (Ribeirao Preto. Online). 2014; 47 (4): 347-356.

  17. Van Brakel WH, Khawas IB, Lucas SB. Reactions in leprosy: an epidemiological study of 386 patients in west Nepal. Lepr Ver. 1994; 65 (3): 190-203.

  18. Lockwood DN, Vinayakumar S, Stanley JN, McAdam KP, Colston MJ. Clinical features and outcome of reversal (type 1) reactions in Hyderabad, India. Int J Lepr Other Mycobact Dis. 1993; 61: 8-15.

  19. Malaviya GN. Shall we continue with nerve trunk decompression in leprosy? Indian J Lepr. 2004; 76 (4): 331-342.

  20. Garbino JA, Nery JA, Virmond M et al. Projeto Diretrizes, Associação Médica Brasileira e Conselho Federal de Medicina/Guidelines Project: Brazilian Medicine Association and Federal Medicina Council. Acta Oncol Bras. 2003; 23 (2): 453-453.

  21. Brasil. Ministério da Saúde. Secretaria de Políticas de Saúde. Departamento de Atenção Básica. Manual de Cirurgias, Brasília. 2002, 11-18.

  22. Agrawal A, Joharapurkar SR, Pandit L et al. Leprosy, nerves, and surgery. Infect Dis Clin Pract. 2008; 16: 345-348.

  23. Van Veen NHJ, Schreuders TAR, Theuvenet WJ et al. Decompressive surgery for treating nerve damage in leprosy. A Cochrane review. Lepr Ver. 2009; 80: 3-12.

  24. Portaria 149 do Ministério da Saúde: “Diretrizes para vigilância, atenção e eliminação da Hanseníase como problema de saúde pública”.




2020     |     www.medigraphic.com